Review of photon and proton radiotherapy for skull base tumours by Fossati, Piero et al.
reports of practical oncology and radiotherapy 2 1 ( 2 0 1 6 ) 336–355
Available  online  at  www.sciencedirect.com
ScienceDirect
jo ur nal home p ag e: ht tp : / /www.e lsev ier .com/ locate / rpor
Review
Review  of photon  and  proton  radiotherapy  for  skull
base tumours
Piero Fossatia,b,∗, Andrea Vavassoria, Letizia Deantonioc,d,
Eleonora Ferrarac, Marco Krengli b,c,d, Roberto Orecchiaa,b
a Radiotherapy Division, IEO, Milan, Italy
b Centro Nazionale Adroterapia Oncologica (CNAO), Pavia, Italy
c Radiotherapy Division, University Hospital “Maggiore della Carità”, Novara, Italy
d Department of Translational Medicine, University of “Piemonte Orientale”, Novara, Italy
a  r  t  i  c  l  e  i  n  f  o
Article history:
Received 12 October 2015
Received in revised form
1  March 2016
Accepted 30 March 2016
Available online 16 April 2016
Keywords:
Skull base tumours
a  b  s  t  r  a  c  t
An extremely large variety of benign and malignant tumours occur at skull base; these
tumour lesions are in the proximity to structures deputed to relevant physiologic func-
tions, limiting extensive surgical approaches to this body district. Most recent progresses
of  surgery and radiotherapy have allowed to improve local control with acceptable rates of
side effects. Various photon radiotherapy techniques are employed, including 3-dimensional
conformal radiotherapy, intensity modulated radiotherapy (IMRT), stereotactic radiotherapy
(SRT) and brachytherapy that is manly limited to the treatment of primary or recurrent
nasopharyngeal carcinoma. Proton beam radiotherapy is also extensively used thanks to
its  physical characteristics. Our review, focusing in particular on meningioma, chordoma,Radiotherapy
Technique
and chondrosarcoma, suggests that proton therapy plays a major role in the treatment of
malignant tumours whereas photon therapy still plays a relevant role in the treatment of
benign tumour lesions.
©  2016 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o. All rights reserved.
body districts. For these reasons, only the most recent pro-1.  Background
The base of skull is a structure at the interface between the
intracranial content and the rest of the body where a num-
ber of neoplasms can arise from tissues of various origin
including meningeal sheets, bone, cartilage, soft tissues, mus-
cles, lymphatic tissue, mucosal epithelium, nerves and nerve
sheets and embryonic remnants. This explains the extremely
large variety of benign and malignant tumours occurring at
∗ Corresponding author at: Radiotherapy, Istituto Europeo di Oncologia,
E-mail address: piero.fossati@ieo.it (P. Fossati).
http://dx.doi.org/10.1016/j.rpor.2016.03.007
1507-1367/© 2016 Greater Poland Cancer Centre. Published by Elsevier this anatomic site. A peculiar aspect of the skull base lesions
is the proximity to structures deputed to relevant physio-
logic functions, like the temporal lobes, brainstem, cranial
nerves, major vessels, pituitary gland, and inner and middle
ears, limiting extensive surgical approaches aimed to achieve
a really radical oncologic result, otherwise possible in other via Ripamonti, 435, 20141 Milano, Italy. Tel.: +39 0382 078505.
gresses of surgery and radiotherapy have allowed to improve
the results in terms of local control with acceptable rates of
side effects and complications.1 In order to obtain acceptable
Sp. z o.o. All rights reserved.
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Brainstem Entire organ < 54 Gy,
Dmax < 64 Gy
Dmax < 15 Gy
D1cc < 10 Gy
Dmax
Centre ≤ 53 Gy (RBE)
Surface ≤ 64 Gy (RBE)
Mayo 20102, Timmerman
20087, Munzenrider 19999
Optic pathways Entire organ < 55 Gy Dmax < 10 Gy
D0.2cc < 8 Gy
Dmax
≤56–60 Gy (RBE)
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constraints in the range
from V45 < 15 cc to V40 < 55
have been suggested
V12 < 5–10 c
ates of local control, malignant tumours in the skull base
ust be irradiated to a dose that exceeds the constraints of
he above listed organs at risk (OARs). In case of a benign
isease, doses employed can be lower and comparable to the
olerance of OARs but the long prognosis raises the issues of
ong-term side effects. A complete review of skull base dose
onstraints is beyond the scope of the present work; however,
able 1 summarizes dose constraints to the most significant
ARs commonly used in clinical practice for photons and pro-
ons, considering both conventional fractionation and short
ourse treatments for photons.2–11
.  Aim
he purpose of this paper is to review the techniques and
he main results of photon and proton radiotherapy for
he treatment of skull base tumours. To highlight strengths
nd disadvantages of different techniques, we have selected
eningioma and chordoma/chondrosarcoma as examples of
enign and malignant diseases in this region.
.  Materials  and  methods
 literature search was performed in Pubmed using the follow-
ng keywords (meningioma or chordoma or chondrosarcoma
r skull-base or nasopharyngeal carcinoma and radiotherapy
r radiation or radiosurgery or SRT or brachytherapy or pro-
on therapy). In principle, papers published since 2000 were
elected, listed and analysed for relevance based on their
bstract. Case reports were excluded, whereas review papers
ere analysed.
.  Results
.1.  Photon  radiotherapy
.1.1.  Intensity  modulated  radiation  therapy  (IMRT)
ntensity modulated radiotherapy (IMRT) represents an
dvanced modality of 3-dimensional conformal radiotherapy
3D-CRT) and it is employed for the treatment of many  dif-
erent tumours, in particular in the case of irregular target≤63 Gy (RBE) Lawrence 2010 , Wenkel
200011
shapes and closeness to critical structures.12 The advantage
of using IMRT for skull base tumours is evident because of the
proximity of various sensitive anatomic structures, such as
the brainstem, optic nerves and chiasm and brain tissue.13
IMRT involves a treatment delivery employing hundreds or
thousands of small beams, created by a multi leaf collimator
(MLC), each with intensity generated using an inverse treat-
ment planning system. Inverse planning involves a process
that uses computer optimization techniques aimed to modu-
late intensities across the target volume and normal tissues,
starting from a specified dose distribution14 and reaching the
desiderate outcome.15 As a result, a high dose conformation is
reached and delivered to irregularly shaped targets, while the
dose to surrounding non-target structures is minimized.12
IMRT can be delivered in different ways: (a) IMRT  with static
field segments (step and shoot), where the field is divided
into different segments and radiation is delivered after the
leaves movement  to create the next segment; (b) with dynamic
delivery (sliding windows), in which the leaves move across
the field during treatment and the time-dependent position
of each leaf determines the intensity; and (c) with rotational
technique using volumetric modulated arc therapy (VMAT) or
tomotherapy; in VMAT, the MLC has the leaf pattern changing
continuously as the gantry rotates, allowing the simultaneous
variation in dose rate, and in tomotherapy, the gantry con-
tinuously rotates while the patient couch is translated in the
rotation plane.16
A pre-requisite of such a sophisticated technology is the
importance of precise targeting and delivering of daily RT
because of the steep gradients between high and low-dose
regions. The advent of image  guided RT (IGRT) allowed a target
position correction, performing imaging prior to each radia-
tion fraction.17
4.1.2.  Stereotactic  radiotherapy
Stereotactic radiotherapy (SRT) dates back to the early ‘50s
with the pioneering experience of Leksell in Sweden.18 Orig-
inally, it was defined as the delivery of high RT dose with
multiple entrance portals, a steep dose gradient, optimal
sparing of surrounding tissues and a precise patient immobi-
lization. Immobilization was achieved with invasive fixation
of the patient anatomy to an external rigid stereotactic frame,
which made fractionated treatment impractical. Treatment
d rad338  reports of practical oncology an
schedule were either of a single (stereotactic radiosurgery SRS)
or of a limited (between 3 and 5) number of fractions (stereo-
tactic radiotherapy SRT). More  recently, the advances in image
guidance have been employed to reposition the patient with
sub-millimetric accuracy without rigid fixation and deliver
SRT without invasive procedures. This so-called frameless
stereotactic radiotherapy enabled delivery of fractionated
treatment schedules.19 In modern clinical practice, SRT can
be delivered either with multiple cobalt sources: gamma knife
(GK) (Elekta Instruments AB, Stockholm, Sweden) or with lin-
ear accelerators (LINACs). There are commercially available
dedicated machines, such as CyberKnife (CK) (Accuray, Sun-
nyvale, CA, USA) that is a small LINAC mounted on a 6 degree
of freedom robotic arm, but also general purpose accelerators
can be used. In SRT, multiple beams are focused on the target
volume from different angles in an isocentric way. Typically, no
inverse planning is performed and, therefore, a non-uniform
dose is achieved with a gradient between the centre and the
periphery of the tumour. Dose prescription is not done accord-
ing to ICRU reports but according to isodose prescription and
concave dose distributions cannot be achieved.20
Cyberknife, even though usually listed as a SRT modality,
can be considered to be at the border between IMRT and SRT as
it uses inverse planning, and, thanks to its ability to perform
non-isocentric treatments, can deliver concave or even donut
shaped dose distributions.21
4.1.3.  Clinical  results  with  photon  external  beam
radiotherapy  (EBRT)
Several clinical series are available on the use of EBRT in
patients with skull base tumours. For the present review,
we focused on meningioma, chordoma, and chondrosar-
coma. Meningioma is typically treated with doses comparable
to OARs tolerance, whereas chordoma and chondrosarcoma
need substantially higher doses.
For meningioma, 102 papers were selected and 37 articles
reporting data of more  than 20 patients were specifically ana-
lysed.
Dosimetric and clinical data of more  than 5000 patients
treated with stereotactic radiotherapy with long term follow-
up are reported in Table 2.13,22–57 Local control for benign
meningioma is typically in the range of 80–90% with min-
imal toxicity. Atypical and malignant meningioma have a
significantly worse outcome and may be candidate to alter-
native or experimental approaches. Radiotherapy has been
used as alternative to surgery or in post-operative setting or
as a salvage treatment. Technique and fractionation are cho-
sen according to the availability and clinical judgement but
an underlying pattern is evident with fractionated treatment
typically used for lesions that are larger and or close to OARs
and IMRT  used for lesion of complex shape.
A recent clinical series with a 10 years follow-up time
analysed 507 patients with skull base meningioma treated
by IMRT  (131 patients) or fractionated stereotactic RT (376
patients).38 Local control for the whole cohort was 94% at 5
years and 88% at 10 years. The treatment technique did not
affect progression-free survival. This is the first study, with
such a long follow-up, that analysed the impact of treatment
on the quality of life and showed that it was unchanged in
47.7% of the patients, and improved in 37.5%. Late toxicity withiotherapy 2 1 ( 2 0 1 6 ) 336–355
such a long follow-up was observed in only 3% of patients.
This large clinical series confirmed the improvement of vol-
ume  conformity and normal tissue protection with highly
conformal RT techniques, and reported, in 87% of patients’
self-reported outcome, unimpaired or improved quality of life.
For chordoma and chondrosarcoma, 18 papers were
selected and 7 articles reporting data of more  than 10
patients were specifically analysed. Results are summarized
in Table 3.58–68 For these diseases, particle therapy has been
historically employed, results in terms of local control and
progression free survival with photons RT are acceptable for
chondrosarcoma but were on average rather disappointing for
chordomas with only one series reporting 5-year local control
in excess of 80% and other series reporting local control or pro-
gression free survival from 15% to 66%. It is difficult to draw
any conclusions from these scarce and heterogeneous data;
nevertheless, outcome appears not to be equivalent to that
of particles and these findings may suggest that even modern
advanced photons cannot achieve adequate target coverage in
the skull base for prescription doses in excess of 70 Gy.
4.1.4.  Brachytherapy
Although most tumours in the skull base are treated with
external beam radiotherapy (EBRT) exclusively, in some cases
a boost with intracavitary or interstitial implants can be used.
The niche for brachytherapy in the skull base is basically
limited to nasopharyngeal carcinoma.69,70
Generally, only patients affected by primary or recur-
rent superficial nasopharyngeal tumours with thickness not
exceeding 10 mm and not involving the bone or the infratem-
poral space, are ideal candidates for brachytherapy.
Brachytherapy is mostly indicated as a boost after EBRT,
offering a confined dose escalation especially for superficially
large tumours (local control is in general considered highly
related to the total dose), even if some authors have reported
no advantage when an additional irradiation with brachyther-
apy was combined to EBRT.71,72
Brachytherapy can be used as the sole salvage treatment,
in particular in the case of re-irradiation for local residual
occurring within 6 months, or well circumscribed/non-bulky
recurrent disease diagnosed after achievement of com-
plete remission with radical radiotherapy.73–76 Very selected
nasopharyngeal recurrence from other skull base tumours
may also be candidate to brachytherapy reirradiation.77
Compared to conventional EBRT, the main advantages of
temporary or permanent brachytherapy, bringing the radia-
tion sources directly near and/or into the tumour include a
higher localized dose around the target volume and a shorter
overall treatment time. The rapid fall-off of doses around
sources allows relative sparing of critical normal tissues. The
main disadvantage is a potential not-treatment of foci of can-
cer in areas outside the treated volume encompassed by the
isodose surface corresponding to the minimal target dose.
Even with brachytherapy, the anatomical challenges of this
site remain relevant and a more  sophisticated technique is
beneficial: Ren et al. demonstrated on a large population of
patients treated with brachytherapy boost after EBRT that
3D-HDR was more  effective than 2D-HDR techniques, with a




































Table 2 – Results of the main series of meningioma treated with photon radiation therapy.
Author Year of
publication








2000 46 Gamma knife 9–25 Gy margin dose
in single fraction
48  LC 96% Minimal toxicity:
1 case (2%) of transient
paresis,
1 case (2%) of
hypopituitarism
No  difference in outcome in




2006 36 Gamma knife 9–25 Gy margin dose
in single fraction



























LC 97.4% for 3D-CRT;
LC 94.4% for GK
No significant toxicity in
3D-CRT group,
1 transient stroke in GK
group
Pts treated with GK had
smaller tumours, there was
no apparent difference in
outcome between the two
modalities
Kreil et al.25 2005 200 Gamma knife 7–25 Gy in single
fraction prescription
20–80% isodose
95  (median) Actuarial
5y LC 98.5% 10y LC
97.2%
1 pt (0.5%) with worsening
cranial nerve symptoms
SRS  may replace surgery in
selected cases
Han et al.26 2008 63 Gamma knife 7–20 Gy margin dose
in single fraction
77  LC 94% 2 pts (2%) had recurrent
seizures,
10 pts (16%) had worsening
of cranial nerves symptoms




Igaki et al.27 2009 98 Gamma knife 14–18 Gy in single
fraction prescription
40–50% isodose
53  (median) Actuarial
5y LC 87% 10y LC
79%
4 pts (4%) with worsening of
cranial nerve symptoms
Tumour volume smaller
than 4 cc and complete
target coverage were
associated with better LC
Nakaya
et al.28
2010 44 Gamma knife 13 Gy margin dose in
single fraction
60 (median) LC 100% 1 pt (worsening of
neurological deficit)
SRT can be an alternative to




2012 251 Gamma knife Mean margin dose
15.8 ± 2 Gy
62.9 98.8% Toxicity in 23 patients (9.2%):
cranial nerves deficit 15 pts,
headache 5 pts, hemiparesis
5 pts, seizure 4 pts, cyst
formation 1 pts, stroke 1 pts
Long follow up is needed,
local recurrence were









2 pts (4.7%) with toxicity
(actuarial 7y LC 89.7%)
No difference in outcome in
post operative vs. radical
treatment
Selch et al.31 2004 45 LINAC SRT 42.5–54 Gy
(2 Gy/fr), 90% isodose




















































fSRT: 45–50 Gy in
(1.8–2 Gy/fr);
SRS 13–15 Gy at
80–90% isodose
73  (median) Actuarial
5y, 10y and 15y DFS:
98.8%, 92.3%, 92.3%
No  sever toxicity, only
transient events
All  tumours were in the
cavernous sinus, larger
lesion and lesion close to
optic pathways were
treated with SRT. There was
no difference in outcome
between SRS and SRT





37.5% of the patients
showed grade I  or II late
fatigue or headache
Fractionated SRT is used for
tumours close to OAR, there
may be a relevant selection
bias when comparing with
SRS
Soldà et al.34 2013 145 LINAC fSRT 50–55 Gy
(1.5–1.66 Gy/fr)
43  (median) Actuarial
5y LC 93% 10y LC
86%
8 pts (3.5%) worsening
vision, 1 pt (0.5%) trigeminal
neuralgia, 2 pts (1%)
cognitive
impairment, 2 pts (1%)
cerebrovascular accidents










88  (median) Actuarial
5y LC 96% 10y LC
95%
10 pts (7%) had significant
toxicity:
- 2 pts developed brain
necrosis and 1 pt died of it,
- 2 pts developed bilateral
optic neuropathy and
blindness,
- 1 pt developed unilateral
retinopathy an impaired
vision
- 1 pt developed cataract,
- 1 pt developed
hydrocephalus and
necessitated a shunt,
- 1 pt developed
osteomyielitis of ear canal
and required surgical
debridement,
- 1 pt died of steroid therapy
complications
All  tumours where WHO
grade I. There was no
difference in outcome
between post operative and
definitive RT. Fractionated
SRT is a treatment option
for patients not candidate
to radical surgery or SRS
Litré et al.36 2009 100 LINAC fSRT 45 Gy (1.8 Gy/fr) 33 Actuarial
7y LC 94%
Toxicity in 23 patients(9.2%):
cranial nerves deficit 15 pts,
headache 5 pts, hemiparesis
5 pts, seizure 4 pts, cyst
formation 1 pt, stroke 1 pt
All tumours where in the
cavernous sinus,
fractionated SRT is the first






















































36  (median) Actuarial 5YPFS
96.9%
Late grade III toxicity 2.7% Radiotherapy may be an
alternative to surgery, for
large tumours or tumours
close to critical structures









107 (median) Actuarial 5y LC 95%
10y LC 88%
QOL was decreased due to





53%). Small lesions may be
treated with SRS, lesion
close to critical organ may
benefit from fSRT, complex
shape lesion may benefit
from IMRT. The choice
between wait and see,
surgery or RT should be




2007 94 IMRT 50.4–62 Gy
(1.8 Gy/fr)
53 (median) 93.6% 4.3% of the pts had
worsening of neurological
symptoms




2011 52 LINAC fSRT 50 Gy (1.66 Gy/fr) 42 (median) Actuarial 5y LC 93% 10 pts (19%) developed
hypopituitarism, 1 pt had
neurocognitive impairment
and 1 pt had increase in
seizure frequency




2009 199 Cyberknife 11–25 Gy in 3–5 fr at
70–90% isodose
30  96.5% Worsening cranial nerve
deficit in 0.5% of the pts
Cyberknife allowed
treatment of pts not
candidate to SRS
Choi et al.41 2010 25 Cyberknife 16–30 Gy in 1–4 fr to
62–91% isodose
28  (median) Actuarial 3y LC 74% 1 pt with brain necrosis,
1 pt with hydrocephalus
All pts were WHO grade II,
post op irradiation may be
beneficial in these subset,




2013 38 Cyberknife 25– 35 Gy in 5
fraction
20 (median) 100% Only transient toxicity Fractionation may be
beneficial for large lesions
Starke
et al.43
2012 225 Gamma knife 8–30 Gy in single
fraction at 28–80%
isodose
78 (median) LC at last FU 86%;
actuarial 5y LC 96%
10y LC 79%
25  pts (10%) had worsening
of neurological symptoms




2001 28 skull base




30  (median) Actuarial 5yPFS 75%;
8y PFS 67%, results
reported for the
whole series (45 pts)




Series include exclusive RT,











































Outcome Toxicity Comments and authors
conclusion
Jalali et al.45 2002 41 LINAC fSRT 50–55 Gy in 30–33
fractions
21 (median) 100% 2 cases of hypopituarism, 2
cases of worsening
neurocognitive impairment,
1 case of worsening visual
field deficit









SRST 23.8–54 Gy in
5–30 fractions
32.5  94.8% (SRS 92% SRT
97.2%)
5 pts had worsening of
pre-existing symptoms
Difference between SRS
and SRT are likely due to
bias in length of follow up
and imaging quality, results
were much worse (tumour




2006 84 LINAC fSRT 50.4–60 Gy
(1.8–2 Gy/fr)
30  (median) 100% Not reported Only WHO grade I, volume
shrinkage depends on
initial tumour volume and
age, young (<56 years)
patient with small tumours
showed more tumour
regression
Brell et al.48 2006 30 LINAC fSRT 50–56 Gy
(2 Gy/fr)




and seizure, 1 pts with short
term memory loss and
dysphasia




2008 563 skull base
pts out of 972
reported
meningiomas
Gamma knife 14 Gy mean
peripheral dose
48 (median) WHO I 93%
WHO II 50%
WHO III 17% (both







2.4%, motor deficit 1.4%,
sensory deficit 0.3% (non
skull base pts included)
SRS can be used for
recurrent meningioma or
as first line treatment
Kollová
et al.50




60 (median) Actuarial 5y LC
97.9%
Permanent morbidity in
5.7% of the patients
Marginal dose of less than




2007 115 Gamma knife 7.5–17 Gy margin
dose
62 (median) Actuarial 5y LC 94%;
10y LC 92%
11  pts (12%) had worsening
of pre-existing symptoms or
developed new symptoms

















































2005 277 Gamma knife 10–30 Gy to the
tumour margins
44  WHOI actuarial 5y
LC 87%, 8y LC 75%;
WHO II actuarial 5y
LC 49%;
WHO III actuarial 5y
LC 0%, gross LC 28%
1 case of worsening VII
cranial nerve deficit,
3 cases of transient
trigeminal pain,
3 cases of diplopia
2 cases of weakness (tumour
close to motor cortex)
Tumour grade was the




2002 122 Gamma knife 11–22.5 Gy in single
fraction at 30–65%
isodose
48.9 (median) Actuarial 5y PFS
96.5%
1  case of intracranial
hypertension and worsening
cranial nerve deficit
All  tumours were in the







2000 92 Gamma knife 6–25 Gy at isodose of
30%-70%
30.5 (median) Actuarial 5y-PFS
92.8%
1 case of worsening
trigeminal neuralgia, 1 case
of complex partial seizures
and 1 case of transient
carotid occlusion
Gamma knife can be





2001 56 LINAC SRS 9–18.5 Gy margin
dose in single
fraction
26  (median) 95% 5 pts (9%) had permanent
late toxicity: 1 difficulty in
gait, 2 visual field deficit, 2
cerebral oedema
SRS is indicated both in
adjuvant setting and as first









Actuarial 5y LC WHO
I 96%, WHO II 77%
WHO III 19%
5  pts (2.3%) permanent
toxicity, all in WHO III
tumours
LINAC SRS is an optimal








Gamma knife 12–36 Gy in single
fraction at 50%
isodose
47 (median) Actuarial 5y LC
WHOI 93%, WHO II
68% WHO III 0%
24 pts (13%) had permanent
late toxicity: 15 cranial
nerve deficit, 5 symptomatic
MR detectable parenchyma
change, 2 carotid stenosis, 2
cystic lesion
SRS  can be used in the
treatment of meningioma;
grade II and III tumours
have worse outcome
LC = local control (LC as freedom form tumour progression at last FU); FU = follow up; pt/pts = patient/patients; GK = gamma knife; SRT = stereotactic radiotherapy; fSRT = fractionated SRS;




































Table 3 – Results of the main series of chordoma and chondrosarcoma treated with photon radiation therapy.
Author Year of
Publication








2001 10 Cyberknife or
LINAC SRT
18–24 Gy at 70–80%
isodose in 1–3
fractions




2 pts with tumour
growth






outcome is not reported
with actuarial
calculation. The authors
claim that outcome is as




2000 45 (37 chordomas, 8
chondrosarcomas)












1  case of ischaemic















44  LC at last follow up
66% (extrapolated)













2012 20 (12 in the skull
base)
Cyber knife 18–50 Gy in 1–5
fractions





No  reported toxicity 8 pts had recurrence
after previous RT with
protons (7 pts) or
photons (1pt). Particle
therapy may give better




2011 71 (51 pts first
diagnosis, 20 pts
recurrence after RT)
Gamma knife Marginal dose of
9–16 Gy in recurrent
pts marginal dose of
10–25 Gy in naive pt
60 (median) Treated tumour







from graph at about
60%
4  pts developed
neuropathy
(abducens and
facial) 2 pts with
pituitary
dysfunction
Dose > 15 Gy and tumour
volume < 7 cc correlate
with better outcome.
SRS may be adequate
for smaller tumour, the
author recommend RCT




2010 14 (10 chordomas, 4
chondrosarcomas)
Gamma knife Marginal dose
10–20 Gy






Marginal dose of more
than 16 Gy is needed for

















































2005 29 (25 chordomas, 4
chondrosarcomas)
Gamma
knife  + -EBRT
SRS:  marginal dose
10–20 Gy; EBRT
45–54 Gy
























2011 19 EBRT or FSRT
or IMRT
65–70 Gy in fractions
of 1.8–2 Gy
53 (median) Actuarial 5y LC 83% Not reported Smaller tumour volume










2000 18 EBRT 53–60 Gy with
conventional
fractionation
43  Actuarial 5y PFS 23% Not reported Extended resection and
high dose RT is needed




2013 12 fSRT 48.6–68.4 Gy
(1.8 Gy/fr)
42  (median) Actuarial 5y – PFS
37.5%

















Actuarial 5y LC 88%
for chondrosarcoma,
65% for chordoma









LC = local control (LC as freedom form tumour progression at last FU); FU = follow up; pt/pts = patient/patients; GK = gamma knife; SRT = stereotactic radiotherapy; fSRT = fractionated SRS;
SRS = radiosurgery; fr = fraction; PFS = progression free survival; OAR = organ at risk; DFS = disease free survival; IMRT = intensity modulated radiotherapy.
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When brachytherapy is used as a boost, the total treatment
duration should be condensed to reduce tumour cell repop-
ulation, with a rest period of 1–2 weeks, depending on the
degree of mucositis; the HDR technique is preferred and the
recommended schedule is 2–6 fractions, 2–5 Gy per fraction
(rarely higher), according to the total dose of EBRT (generally
60–70 Gy).
In exclusive HDR BT, the prescribed dose is 20–40 Gy, 2–5 Gy
per fraction, whereas in LDR/PDR BT, a dose rate of 0.4–0.6 Gy/h
is usually selected to administrate about 60 Gy.79,80
Brachytherapy is well tolerated with minimal morbidity:
severe long-term toxicity such as necrosis of the surround-
ing and affiliated tissues of the nasopharynx is reported in
about 7% of patients. Headache and foul odour are the repre-
sentative signs: necrosis is life threatening when the internal
carotid artery is eroded.81 Higher incidence is observed in re-
irradiated patients, with up to 10% of nasopharyngeal necrosis
and endocrine dysfunction.76
For brachytherapy as a boost for nasopharyngeal carci-
noma, 57 papers were selected and 12 articles reporting data
of more  than 20 patients were specifically analysed. Clini-
cal results are summarized in Table 4.71,72,78,82–90 As can be
observed, the outcome of patients treated with brachytherapy
appears superior to that of patients treated with EBRT alone
without increased toxicity. Of course, the difference may be
due to a selection bias as T3 and T4 patients are not candidate
to brachytherapy. The interest in this modality has recently
decreased as results of IMRT  or SRT boost may be equivalent
to those of brachytherapy.
4.2.  Proton  radiotherapy
Protons have physical characteristics that differ from those of
photons. Protons permit better sparing of critical organs due to
their particular ballistic, dose deposition being mainly limited
to the so called Bragg-peak which can be spread-out. Thus, the
integral dose is low and the treatment is extremely conformal
to the target volume. Upon these concepts, protons have been
used for radiation treatment of skull base tumours over the
last decades.
Most of the studies report on the use of passive scatter-
ing technique and only few recent ones on the use of active
delivery systems that allow an even better sparing of healthy
tissue nearby the target. A few articles describe also the
use of a mixed proton/photon beam (Table 59–11,91–102). From
the methodological point of view, the large majority of the
studies are retrospective and may include different tumour
types: chordoma, chondrosarcoma, and meningioma of grade
I–III. We  excluded from our analysis series containing pae-
diatric patients and re-irradiation for relapse after photon
radiotherapy.
Historical data are described in two papers from 1999
about skull base chordoma and chondrosarcoma with a
relevant number of patients that describe the experience of
two institutions pioneering proton radiotherapy in USA: the
Massachusetts General Hospital (MGH) in Boston and Loma
Linda University Medical Center (LLUMC) in Loma Linda.
The first large clinical series of 519 cases of skull chordoma
and chondrosarcoma were reported from MGH in Boston.
Patients were treated to a total dose ranging from 66 toiotherapy 2 1 ( 2 0 1 6 ) 336–355
83 Gy (relative biological effectiveness – RBE) obtained by
multiplying physical dose by the RBE value (usually 1.1 for
protons). Local relapse free survival rates of 73% and 80% at
5 years were observed for chordoma and chondrosarcoma,
respectively, with relatively low toxicity findings.9 The series
treated at LLUMC reviewed the results of 58 patients treated
with proton therapy to a total dose of 65–79 Gy (RBE) after
surgical resection. Local control and overall survival at 5 years
were obtained in 59% and 79%, respectively, for chordoma
and 75% and 100% for chondrosarcoma.91 The review on
chordoma and chondrosarcoma includes the results of proton
radiotherapy delivered after one or more  surgical resections
(Table 59–11,91–102). All series were treated to very high doses
of up to 83 Gy (RBE). The results in terms of local control and
survival at 5 years appear more  favourable for chondrosar-
coma, ranging, respectively, from 75% to 94% and from 91% to
100%, rather than for chordoma, ranging, respectively, from
46% to 81% and from 67% to 81%. Most of the results reported
in the series treated with proton radiotherapy appear more
favourable than those reported after EBRT. Unfavourable
prognostic factors emerging from these series are large target
volume, brainstem compression,91,92 minimal dose to GTV,
and the percentage of tumour volume included in the 95%
isodose.10 In terms of toxicity, literature data describe severe
late side effects in a relatively small percentage of patients
and include brain and brainstem injuries often related to
tissue necrosis, vision and hearing loss, and endocrinopathy
related to pituitary dysfunction.
In the meningioma literature series, the authors report on
the results of patients affected either by benign or atypical
and malignant meningioma. The dose level is quite similar
to that used in the series treated by photon radiotherapy
and the rationale of using protons resides in a potentially
better sparing of the critical structures close to the target
region. Several series include either skull base or convex-
ity lesions and patients with both primary and recurrent
tumours after surgery. Local control at 5 years was obtained in
85–100% of benign skull base meningioma cases and in 47–71%
of atypical/malignant meningioma cases. The occurrence of
long-term side effects is quite low and similar to that of EBRT,
but patient selection was often unfavourable due to inclusion
of many  inoperable cases extending towards critical structures
such as brainstem, temporal lobes, pituitary gland, and optic
nerves.
5.  Discussion
Skull base remains an extremely challenging tumour site.
Generally, IMRT can achieve more  uniform dose distribution
and avoid hot spots, is ideally suited for complex-shaped tar-
gets whereas SRT can achieve a highest dose gradient, and
is ideally suited for targets of a simple shape. On the other
hand, radiosurgery would be more  rationally used in round or
oval lesions that do not abut critical structures. These gen-
eral concepts are supported by in silico treatment plans that
compared fractionated SRT with IMRT, and confirmed IMRT
superiority in avoiding hot spots within the CTV and in obtain-
ing a more  uniform dose distribution.103,104 Also clinical data









































Stage EBRT dose BRT dose CT FU
(months)
LC rate Toxicity


























(A1) 94.9% at 5y
(A2) 94.5% at 5y







2002 (A) BRT boost:
106











HDR 12 Gy/3 fr (A) 55.9%
(B) 71.1%
(A)  31 (12–71)
(B) 43 (12–80)
(A)  86% at 3y





Lee et al.83 2002 (A) 43 pts with
primary tumours
(B) 12 pts with
recurrence
tumours

















(A) 89% at 5y













Stage I-IIb: 36 pts
Stage III-IV: 55
pts
60–70 Gy 12–18 Gy in 4–6 fr
bid
23% 48 Stage I-IIb:
96–100%
Stage III-IV: 65–86%
Synechiae of the nasal
mucosa
Dry-mouth syndrome
Lu et al.85 2004 33 (T1: 22 pts, T2:
11 pts)
Stage II-II: 17 pts
Stage III-IV: 16
pts




29 (17–38) 93.6% at 2y 18% G4 acute toxicity
1% G4 toxicity
Yau et al.86 2004 (A) BRT boost: 24






HDR  10–24 Gy
twice-weekly fr
30% 33 (A) 71% at 3y



















































Stage EBRT dose BRT dose CT FU
(months)
LC rate Toxicity




66  Gy (A) BRT: 10–21 Gy
(5–8 fr)
(B) 15 Gy (5 Gy/fr)




between pts who had
a boost and those who
did not







12–20 Gy NA NA (A)  97% at 5y














(A) T1,2N + 61;
T3,4N0 + 65
(B) T1,2N + 34;
T3,4N0 + 38
(C) T1,2N + 40
T3,4N0 + 36
(A) Vienna EBRT
76 Gy + BT
boost + neadj &
concomit CHT
(B) Rotterdam





76 Gy + concomit
CHT (no boost)
11  Gy All NA T1,2N + EBRT + BT
100% vs EBRT
alone 90%
T3,4N0 + EBRT + BT
89% vs EBRT alone
89%
NA












57.8  (33.9–117) (A) 93.1% at 5y






2014 (A) Induction CT
and RT + CT: 139
(B) Induction CT
and





70  Gy LDR: 11 Gy




29  (2–67) (A) 59.7% at 3y









































Table 5 – Results of the main series of chordoma, chondrosarcoma and meningioma treated with proton radiation therapy.
Author Year of
publication



























- 3 death due to
brainstem injury
- 8 temporal lobe injury
- 12 optic neuropathy
Other toxicities reported:
- hearing loss (2/3 of pts




radiation therapy for skull
base chordoma and low









65–79 GyE 33 5y LC and OS 59% and
79% (chordoma) and
75% and 100% (CS)
Late toxicity ≥ grade 3
(4/58; 7%) LENT SOMA:
- 2 hearing impairment
- 1 temporal lobe injury
- 1 focal seizure
High dose proton RT offers
excellent chances of lasting
tumour control and survival
with acceptable risks.




72  Gy (RBE) 69.3 5y LC rate 46%
5y OS rate 66.7%
5y DFS rate 42%
LC higher for small
tumours (<30 ml): 75%
vs. 50% at 3y and 60%
vs. 0% at 5y
Late ≥ grade 3:
- 2 brain necrosis
-  1 oral mucosa ulceration
PBR  is effective for pts with
skull base chordoma,
especially for those with
small tumours.












- minimum dose to the
tumour
- tumour volume
included n the 95%
isodose
42 late toxicity:
- 8 optic neuropathy
- 11 neuropsychological
disorder
- 21 decreased hearing
-16 pituitary dysfunction
The quality of PBR, reflected
by homogeneity of the dose
into the tumour volume is a
major factor of LC.






73.5 Gy (RBE) for
chordoma
68.4 Gy (RBE) for CS
38 5y LC
-  81% chordoma
- 94% CS
5y DFS
-  81% chordoma
- 100% CS
5y OS
-  62% chordoma
- 91% CS
94%  5-y freedom from
high-grade toxicity
Late toxicity ≥ grade 3
(CTCAE v. 3.0):
- 2 optic neuropathy
- 2 symptomatic temporal
lobe damage
Spot  scanning PBR is safe
and offers high tumour
control rates of skull base
chordoma and CS, similar

























































77.4–79.4  CGE 21 2y LC 86%
2y OS 92%
Unilateral grade 2 hearing
loss toxicity in 18% of pts.
No grade ≥2 optic or
brainstem toxicities
(RTOG/EORTC)













69.8 Gy (RBE) for
chordoma
68.4 Gy (RBE) for CS
27  1 local recurrence
1 distant mts
All pts alive at time of
analysis
At 23 months 1
neurotoxicity grade 2
(numbness of the right
lower lip)
No other subacute or late
toxicity recorded.
In  comparison to passive
scattering, spot scanning










59  CGE 53 5y OS 93%
10y OS 77%
Recurrence free rate 5y
100% and 10y 88%
1 pts died from brainstem
necrosis 22 months after
RT;
Late toxicity ≥3:
- ophthalmologic 4 pts
- neurologic 4 pts
- otologic 2 pts.
Combined proton and












-  SRT 5 pts
- HSRT18pts
20.3 CGE (mean) for
HSRT














Stereotactic PBR is effective
and safe in controlling large
and complex-shape skull
base meningiomas.





60.6  CGE 25.4 4y LC 98%
4y OS 100%








is efficacy in the treatment
of meningiomas, especially















48  5y OS 53.2%
5y LC 46.7%
Mean local relapse free
interval: 27.2 months
1 pt developed radiation
necrosis 16 months after
treatment
Postoperative combination


























































13  CGE prescribed
to 90% isodose line




time to progression 48
months)
3/5 in field progression.
3/50 (5.9%) late toxicity:
- 2 seizure
-  1 panhypopituitarism
Proton SRS is effective for
small benign meningiomas,
with a potentially lower
rate of long-term treatment
related morbidity. Longer
follow-up is needed to









59  Gy (RBE) grade 2
57 Gy (RBE) grade 1
or no histological
verification
74  5y actuarial LC rate 96%
(99% in grade 1 or
absent histological









Fractionated PBR for grade 1
cavernous sinus
meningiomas achieves
excellent control rates with
minimal toxicity regardless
of surgical intervention or













factors: WHO grade and
tumour volume
Late side effects ≥ 3
(CTCAE v 3.0):
- 3 brain necrosis/oedema
interfering with daily
living
- 2 optic neuropathy
(5y Grade ≥ 3 late toxicity
free survival 84.5%)
PBR  is a safe and effective










63  Gy (RBE) 39 5y LC 71.1%
(5y LC 87.5% following
dose > 60 Gy vs. 50% for
≤60 Gy)
5/22 developed in local
tumour progression; all
were in field. (median
time to progression 20
months)




control rates for grade 2
meningiomas. Prospective
studies are needed to
define the optimal RT dose.
CS = chondrosarcoma; CGE = Cobalt Gray equivalent; fx = fraction; LRFS = local recurrence free survival; LC = local control; DFS = disease free survival; OS = overall survival; pt/pts = patient/patients;
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greater than 3.5 cm or with irregular margins, and less than
3–5 mm distance from the optic nerves or chiasm, and abutting
the brainstem.14,105 The ability of IMRT  to achieve excellent
dose distribution for the most complex targets allows mod-
erate dose escalation to the tumour while respecting dose
constraints.106–108 Proton radiotherapy results in an even bet-
ter capability to cover the target while sparing surrounding
critical structures, especially in the case of tumours with chal-
lenging “L” and “C” shapes, compared to photon IMRT  and SRT.
Any radiation technique needs to be combined with an opti-
mal  surgical resection aiming at tumour debulking to reduce
as much of the tumour volume as possible and at achieving
the best geometrical configuration to facilitate the adequate
target coverage.109
For benign tumour, several results of highly advanced pho-
ton techniques are satisfactory in terms of both outcome and
toxicity. On the other hand, for malignant diseases in the base
of skull, proton radiotherapy and, in selected cases, ion ther-
apy can be considered the first treatment option and photons
should be mainly reserved to patient that do not have access
to particle therapy.109
The role of brachytherapy is mainly limited to the treat-
ment of primary and recurrent nasopharyngeal carcinoma
where it can significantly improve the therapeutic window.110
6.  Conclusion
Photon radiotherapy plays a main role in the treatment of
benign skull base lesions such as benign meningioma, IMRT
being more  often used for large and irregularly shaped lesions
and SRT for small round lesions. For malignant tumours,
such as chordoma and chondrosarcoma, proton radiotherapy
should be the first option and photon techniques can be used
when particle therapy is unavailable. Anyway, radiation ther-
apy for skull base tumours requires a special expertise and a
multidisciplinary team for an optimal management.




 e  f  e  r  e  n  c  e  s
1. Mazzoni A, Krengli M. Historical development of the
treatment of skull base tumors. Rep Pract Oncol Radiother
2016;21:319–24.
2. Mayo C, Yorke E, Merchant TE. Radiation associated
brainstem injury. Int J Radiat Oncol Biol Phys 2010;76(March (3
Suppl.)):S36–41.3. Mayo C, Martel MK, Marks LB, Flickinger J, Nam J, Kirkpatrick
J. Radiation dose-volume effects of optic nerves and chiasm.
Int  J Radiat Oncol Biol Phys 2010;76(3 Suppl.):S28–35.iotherapy 2 1 ( 2 0 1 6 ) 336–355
4. Bhandare N, Jackson A, Eisbruch A, et al. Radiation therapy
and hearing loss. Int J Radiat Oncol Biol Phys 2010;76(March (3
Suppl.)):S50–7.
5. Zhou X, Ou X, Xu T, et al. Effect of dosimetric factors on
occurrence and volume of temporal lobe necrosis following
intensity modulated radiation therapy for nasopharyngeal
carcinoma: a case–control study. Int J Radiat Oncol Biol Phys
2014;90:261–9.
6. Su SF, Huang SM, Han F, et al. Analysis of dosimetric factors
associated with temporal lobe necrosis (TLN) in patients
with nasopharyngeal carcinoma (NPC) after intensity
modulated radiotherapy. Radiat Oncol 2013;8:17.
7. Timmerman RD. An overview of hypofractionation and
introduction to this issue of seminars in radiation oncology.
Semin Radiat Oncol 2008;18(October (4)):215–22.
8. Lawrence YR, Li XA, el Naqa I, et al. Radiation dose-volume
effects in the brain. Int J Radiat Oncol Biol Phys 2010;76(March
(3  Suppl.)):S20–7.
9. Munzenrider JE, Liebsch NJ. Proton therapy for tumors of
the skull base. Strahlether Onkol 1999;175(Suppl. 2):57–63.
10. Noel G, Feuvret L, Calugaru V, et al. Chordomas of the base
of the skull and upper cervical spine. One hundred patients
irradiated by a 3D conformal technique combining photon
and proton beams. Acta Oncol 2005;44(7):700–8.
11. Wenkel E, Thornton AF, Finkelstein D, et al. Benign
meningioma: partially resected, biopsied, and recurrent
intracranial tumors treated with combined proton and
photon radiotherapy. Int J Radiat Oncol Biol Phys
2000;48(5):1363–70.
12. Pirzkall A, Debus J, Haering P, et al. Intensity modulated
radiotherapy (IMRT) for recurrent, residual, or untreated
skull-base meningiomas: preliminary clinical experience.
Int  J Radiat Oncol Biol Phys 2003;55:362–72.
13. Milker-Zabel S, Zabel-du Bois A, Huber P, Schlegel W,  Debus
J.  Intensity-modulated radiotherapy for complex-shaped
meningioma of the skull base: long-term experience of a
single institution. Int J Radiat Oncol Biol Phys 2007;68:
858–63.
14. Minniti G, Amichetti M, Enrici RM.  Radiotherapy and
radiosurgery for benign skull base meningiomas. Radiat
Oncol 2009;4:42.
15. Sajja R, Barnett GH, Lee SY, et al. Intensity-modulated
radiation therapy (IMRT) for newly diagnosed and recurrent
intracranial meningiomas: preliminary results. Technol
Cancer Res Treat 2005;4:675–82.
16. Gomez-Millan J, Fernández JR, Medina Carmona JA. Current
status of IMRT in head and neck cancer. Rep Pract Oncol
Radiother 2013;18:371–5.
17. Chen AM, Cheng S, Farwell DG, et al. Utility of daily image
guidance with intensity-modulated radiotherapy for tumors
of  the base of skull. Head Neck 2012;34:763–70.
18. Leksell L. The stereotaxic method and radiosurgery of the
brain. Acta Chir Scand 1951;102:316–9.
19. Brenner DJ, Martel MK, Hall EJ. Fractionated regimens for
stereotactic radiotherapy of recurrent tumors in the brain.
Int J Radiat Oncol Biol Phys 1991;21:819–24.
20. Torrens M, Chung C, Chung HT, et al. Standardization of
terminology in stereotactic radiosurgery: report from the
Standardization Committee of the International Leksell
Gamma Knife Society: special topic. J. Neurosurg
2014;121(Suppl.):2–15.
21. Collins SP, Coppa ND, Zhang Y, Collins BT, McRae DA, Jean
WC. CyberKnife radiosurgery in the treatment of complex
skull base tumors: analysis of treatment planning
parameters. Radiat Oncol 2006;1:46.22. Aichholzer M, Bertalanffy A, Dietrich W,  et al. Gamma knife
radiosurgery of skull base meningiomas. Acta Neurochir
(Wien)  2000;142:647–52.
radioreports of practical oncology and 
23. Zachenhofer I, Wolfsberger S, Aichholzer M, et al.
Gamma-knife radiosurgery for cranial base meningiomas:
experience of tumor control, clinical course, and morbidity
in  a follow-up of more than 8 years. Neurosurgery
2006;58:28–36.
24. Metellus P, Regis J, Muracciole X, et al. Evaluation of
fractionated radiotherapy and gamma knife radiosurgery in
cavernous sinus meningiomas: treatment strategy.
Neurosurgery 2005;57:873–86.
25. Kreil W,  Luggin J, Fuchs I, Weigl V, Eustacchio S,
Papaefthymiou G. Long term experience of gamma knife
radiosurgery for benign skull base meningiomas. J Neurol
Neurosurg Psychiatry 2005;76:1425–30.
26. Han JH, Kim DG, Chung HT, et al. Gamma knife radiosurgery
for skull base meningiomas: long-term radiologic and
clinical outcome. Int J Radiat Oncol Biol Phys 2008;72:
1324–32.
27. Igaki H, Maruyama K, Koga T, et al. Stereotactic radiosurgery
for  skull base meningioma. Neurol Med Chir (Tokyo)
2009;49:456–61.
28. Nakaya K, Niranjan A, Kondziolka D, et al. Gamma knife
radiosurgery for benign tumors with symptoms from
brainstem compression. Int J Radiat Oncol Biol Phys
2010;77:988–95.
29. Pollock BE, Stafford SL, Link MJ, Garces YI, Foote RL.
Single-fraction radiosurgery for presumed intracranial
meningiomas: efficacy and complications from a 22-year
experience. Int J Radiat Oncol Biol Phys 2012;83:1414–8.
30. Chuang CC, Chang CN, Tsang NM, et al. Linear
accelerator-based radiosurgery in the management of skull
base  meningiomas. J Neurooncol 2004;66:241–9.
31. Selch MT, Ahn E, Laskari A, et al. Stereotactic radiotherapy
for treatment of cavernous sinus meningiomas. Int J Radiat
Oncol Biol Phys 2004;59:101–11.
32. Correa SF, Marta GN, Teixeira MJ. Neurosymptomatic
carvenous sinus meningioma: a 15-years experience with
fractionated stereotactic radiotherapy and radiosurgery.
Radiat Oncol 2014;9:27.
33. Kaul D, Budach V, Misch M, Wiener E, Exner S, Badakhshi H.
Meningioma of the skull base: long-term outcome after
image-guided stereotactic radiotherapy. Cancer Radiother
2014;18:730–5.
34. Soldà F, Wharram B, De Ieso PB, Bonner J, Ashley S, Brada M.
Long-term efficacy of fractionated radiotherapy for benign
meningiomas. Radiother Oncol 2013;109:330–4.
35. Tanzler E, Morris CG, Kirwan JM, Amdur RJ, Mendenhall
WM. Outcomes of WHO Grade I meningiomas receiving
definitive or postoperative radiotherapy. Int J Radiat Oncol
Biol Phys 2011;79:508–13.
36. Litré CF, Colin P, Noudel R, et al. Fractionated stereotactic
radiotherapy treatment of cavernous sinus meningiomas: a
study of 100 cases. Int J Radiat Oncol Biol Phys 2009;74:1012–7.
37. Hamm K, Henzel M, Gross MW, Surber G, Kleinert G,
Engenhart-Cabillic R. Radiosurgery/stereotactic
radiotherapy in the therapeutical concept for skull base
meningiomas. Zentralbl Neurochir 2008;69:14–21.
38. Combs SE, Adeberg S, Dittmar JO, et al. Skull base
meningiomas: long-term results and patient self-reported
outcome in 507 patients treated with fractionated
stereotactic radiotherapy (FSRT) or intensity modulated
radiotherapy (IMRT). Radiother Oncol 2013;106:186–91.
39. Minniti G, Clarke E, Cavallo L, et al. Fractionated stereotactic
conformal radiotherapy for large benign skull base
meningiomas. Radiat Oncol 2011;6:36.
40. Colombo F, Casentini L, Cavedon C, Scalchi P, Cora S,
Francescon P. Cyberknife radiosurgery for benign
meningiomas: short-term results in 199 patients.
Neurosurgery 2009;64(2 Suppl.):A7–13.therapy 2 1 ( 2 0 1 6 ) 336–355 353
41. Choi CY, Soltys SG, Gibbs IC, et al. Cyberknife stereotactic
radiosurgery for treatment of atypical (WHO grade II)
cranial meningiomas. Neurosurgery 2010;67:
1180–8.
42. Oermann EK, Bhandari R, Chen VJ, et al. Five fraction
image-guided radiosurgery for primary and recurrent
meningiomas. Front Oncol 2013;3:213.
43. Starke RM, Williams BJ, Hiles C, Nguyen JH, Elsharkawy MY,
Sheehan JP. Gamma knife surgery for skull base
meningiomas. J Neurosurg 2012;116:588–97.
44. Pourel N, Auque J, Bracard S, et al. Efficacy of external
fractionated radiation therapy in the treatment of
meningiomas: a 20-year experience. Radiother Oncol
2001;61:65–70.
45. Jalali R, Loughrey C, Baumert B, et al. High precision focused
irradiation in the form of fractionated stereotactic
conformal radiotherapy (SCRT) for benign meningiomas
predominantly in the skull base location. Clin Oncol (R Coll
Radiol) 2002;14:103–9.
46. Torres RC, Frighetto L, De Salles AA, et al. Radiosurgery and
stereotactic radiotherapy for intracranial meningiomas.
Neurosurg Focus 2003;14:e5.
47. Henzel M, Gross MW, Hamm K, et al. Significant tumor
volume reduction of meningiomas after stereotactic
radiotherapy: results of a prospective multicenter study.
Neurosurgery 2006;59(December (6)):1188–94 [discussion
1194].
48. Brell M, Villà S, Teixidor P, et al. Fractionated stereotactic
radiotherapy in the treatment of exclusive cavernous sinus
meningioma: functional outcome, local control, and
tolerance. Surg Neurol 2006;65:28–33 [discussion 33-4].
49. Kondziolka D, Mathieu D, Lunsford LD, et al. Radiosurgery
as definitive management of intracranial meningiomas.
Neurosurgery 2008;62:53–8 [discussion 58-60].
50. Kollová A, Liscák R, Novotný Jr J, Vladyka V, Simonová G,
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